How do you treat de novo metastatic hepatocellular carcinoma in a non-cirrhotic patient with a prior orthotopic liver transplant for hepatitis B now on chronic immunosuppression?
Answer from: Medical Oncologist at Community Practice
Given the risk of allogeneic rejection in these patients, I avoid immune checkpoint inhibitors. Larger trials are needed to confirm the safety of these agents in this population; a small pilot study of 7 patients with metastatic HCC s/p liver transplant did report 2 patients with rejection. Therefor...
Comments
Medical Oncologist at Mayo Clinic, Rochester I agree with @Autumn J. McRee. The data is limited...
I agree with @Autumn J. McRee. The data is limited...